Pharmacy Times

JUNE 24, 2024

Shahida Choudhry, PharmD, shares her journey in pharmacy ownership.

144

144

STAT

JUNE 24, 2024

Suicide rates in the United States increased approximately 36% between 2000 and 2022, according to updated data from the National Center for Health Statistics. Suicide was responsible for just under 50,000 deaths in 2022 (the last year with complete statistics) — an all-time high. As this appalling trend continues, offering mental health assessments and care in primary care settings could help save lives.

144

144

Pharmacy Times

JUNE 24, 2024

Teplizumab (Tzield; Sanofi) has the potential to delay type 1 diabetes and the onset of stage 3 diabetes, but must be started in stage 1 of the disease.

139

139

STAT

JUNE 24, 2024

Bird flu snapshot: This is the second installment in a series of regular updates on H5N1 avian flu that STAT is publishing on Monday mornings. To read future updates you can also subscribe to STAT’s Morning Rounds newsletter. As the H5N1 outbreak in dairy herds approaches the three-month mark, America’s top animal health official is calling on farmers to step up the use of personal protective equipment, limit traffic onto their farms, and increase cleaning and disinfection practice

140

140

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

Fierce Healthcare

JUNE 24, 2024

The Department of Health and Human Services (HHS) is locking in its enforcement strategy to keep healthcare providers from blocking access to electronic health information. | Providers found to have committed information blocking will face financial repercussions tied to Medicare program participation as well as the public disclosure of the enforcement.

Hospitals 132

Hospitals 132

STAT

JUNE 24, 2024

Alnylam Pharmaceuticals said Monday that its treatment for an increasingly common heart condition cut the risk of death and recurrent cardiovascular complications in a key Phase 3 study, paving the way for the likely approval of the drug. Specifically, on that composite primary endpoint, the drug, called vutrisiran, reduced the risk by 28% compared with placebo in the overall trial population, which included some people who were already taking a treatment for the disease considered the standard

Labelling 133

Labelling 133

STAT

JUNE 24, 2024

WASHINGTON — He hardly seems the part of the telehealth industry’s public enemy No. 1. He’s unassuming, self-effacing, soft-spoken, with the bearing of a professor. But as telehealth lobbyists seize on this moment years after pandemic lockdowns to win new protections and incentives from Capitol Hill, Ateev Mehrotra is the industry’s chief critic — determined to warn congressional committees that the booming virtual care business comes with tradeoffs.

130

130

Fierce Pharma

JUNE 24, 2024

In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events in patient | In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events.

127

127

STAT

JUNE 24, 2024

When a new medical device hits the market, there’s typically still some uncertainty about whether it works. Device makers generally do not have to submit as much, or as rigorous, clinical data to the Food and Drug Administration as their biotech counterparts. Once FDA regulators decide a device is safe and effective, companies and researchers then attempt to track how the device performs in the real world.

Insurance 127

Insurance Hospitals FDA 127

Fierce Pharma

JUNE 24, 2024

After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. | After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. And what better way to do it than to win a major contract in your rival’s home country? The U.K. government has selected Pfizer to supply 5 million doses of its RSV shot Abrysvo over the next two years.

Vaccines 126

Vaccines 126

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JUNE 24, 2024

Explore how digital twins are transforming healthcare and drug discovery, with success stories showcasing their impact in the biopharma industry. Learn about their journey from concept to real-world applications.

124

124

STAT

JUNE 24, 2024

On Tuesday, shares of Grail, the liquid biopsy company that hopes that its test, Galleri, will be widely used to screen for cancer, will become a publicly traded stock (with the ticker GRAL) that any investor can buy or sell on the Nasdaq. That will, in a sense, end a long, strange trip that has taken a decade. Grail was spun out by the DNA sequencing giant Illumina in 2015.

123

123

Fierce Pharma

JUNE 24, 2024

Following Novo Nordisk’s recent Wegovy approval to cut heart risks in adults with obesity, Eli Lilly appears to be homing in on the next potential label expansion for its rival GIP/GLP-1 weigh | Late last week, Lilly shared detailed results from its phase 3 SURMOUNT-OSA study, which found that Zepbound at the 10 mg and 15 mg doses aced its primary and secondary endpoints in obese patients with obstructive sleep apnea (OSA).

Labelling 119

Labelling FDA 119

Fierce Healthcare

JUNE 24, 2024

Higher care costs directly following a hospital merger have a downstream effect of local employers laying off a portion of their workers, according to a new National Bureau of Economic Researc | A new analysis ties merger-driven hospital price increases to higher employer insurance premiums and subsequent headcount reductions.

Hospitals 116

Hospitals Insurance 116

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

JUNE 24, 2024

New research shows that, in spite of recommendations discouraging use of aspirin in primary prevention of cardiovascular disease among older adults, nearly a third of adults 60 years and older are still using it for this very purpose. The study , published on Monday in Annals of Internal Medicine, found that 18.5 million adults 60 and older without cardiovascular disease reported using preventative aspirin in 2021.

115

115

Pharmacy Times

JUNE 24, 2024

Benefits of semaglutide on cardiovascular outcomes, such as death, non-fatal myocardial infarction, and non-fatal stoke, were also presented at the session at American Diabetes Association 84th Scientific Sessions.

111

111

STAT

JUNE 24, 2024

The results of a randomized controlled trial published Monday showed oral ketamine tablets were safe and effective for patients with treatment-resistant depression — the latest attempt by researchers to rigorously evaluate psychedelic drugs’ role in treating conditions like depression, anxiety and post-traumatic stress disorder. In the Phase 2 trial, the results of which were detailed in Nature Medicine , patients who took extended release ketamine tablets at an 180mg dosage twice

Dosage 114

Dosage 114

Fierce Healthcare

JUNE 24, 2024

UnitedHealthcare is betting big on its Surest unit as the insurer releases new data on where the plan has seen success in the past several years. | UnitedHealthcare is betting big on its Surest unit as the insurer releases new data on where the plan has seen success in the past several years.

Insurance 111

Insurance 111

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmacy Times

JUNE 24, 2024

Compared to placebo, nicotinamide riboside significantly improved the 6-minute walking capabilities in patients with decreased endurance and muscle function due to peripheral artery disease.

111

111

Fierce Healthcare

JUNE 24, 2024

Digital health company Sharecare has agreed to be acquired by private equity firm Altaris for $1.43 in cash per share, or about $518 million. | Digital health company Sharecare has agreed to be acquired by private equity firm Altaris for $1.43 in cash per share, or about $518 million.

111

111

pharmaphorum

JUNE 24, 2024

Bristol-Myers Squibb’s KRAS inhibitor Krazati has been approved for a second indication, colorectal cancer

FDA 111

FDA 111

Fierce Pharma

JUNE 24, 2024

Following a yearslong back-and-forth in the courts, a clutch of major drugmakers will get to re-challenge allegations that the companies helped fund terrorism through their business dealings in Ira | After a long legal dispute, a clutch of major drugmakers will get to re-challenge claims that they helped fund terrorism through their business dealings in Iraq.

110

110

pharmaphorum

JUNE 24, 2024

Fenofibrate, a decades-old drug used to lower cholesterol levels, has been shown to reduce the progression of diabetic retinopathy in a large-scale trial.

111

111

PharmaVoice

JUNE 24, 2024

With a career focused on striking deals, Kaan Cartel is hoping to lead the Flagship-backed biotech with an mRNA platform into its next phase of growth.

106

106

pharmaphorum

JUNE 24, 2024

Alnylam shares spike after vutrisiran aces HELIOS-B trial in ATTR-cardiomyopathy, setting up regulatory filings

111

111

Pharmaceutical Technology

JUNE 24, 2024

The osteoporosis market is expected to grow at a compound annual growth rate of 5.4% from 2023 to 2032, reaching $17.9bn across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) by the end of this forecast period, according to leading data and analytics company GlobalData’s recent report: Osteoporosis: Seven-Market Drug Forecast and Market Analysis.

Compounding 105

Compounding 105

pharmaphorum

JUNE 24, 2024

Novo Nordisk boosts manufacturing capacity for GLP-1 drugs again, unveiling a $4.

109

109

The Checkup by Singlecare

JUNE 24, 2024

If you have recurring back or neck pain or are dealing with an acute muscle spasm, over-the-counter pain medications, like ibuprofen , can offer much-needed relief. When those treatments still aren’t taking the edge off, your healthcare provider might prescribe something stronger, such as cyclobenzaprine. Also known by the brand name Flexeril, this medication is FDA approved to treat muscle spasms associated with painful musculoskeletal conditions.

FDA 105

FDA 105

Pharmaceutical Commerce

JUNE 24, 2024

The latest news for pharma industry insiders.

105

105

pharmaphorum

JUNE 24, 2024

Daiichi Sankyo has a second approval in Japan for Ezharmia, its first-in-class dual EZH1 and EZH2 inhibitor, as a treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL).Ezharmia (valemetostat tosylate) remains the first and only drug in the class to be approved for marketing around the world, having been cleared in Japan in 2022 for relapsed or refractory adult T-cell leukaemia/lymphoma (ATL).

105

105

Pharmaceutical Commerce

JUNE 24, 2024

A study examines the economical validity of using this therapy as a treatment for unresectable stage III non–small cell lung cancer.

105

105

Fierce Healthcare

JUNE 24, 2024

The Supreme Court will not hear a legal challenge to the nearly $2.7 billion Blue Cross Blue Shield settlement. | The Supreme Court will not hear a legal challenge to the nearly $2.7 billion Blue Cross Blue Shield settlement.

105

105

Pharmacy Times

JUNE 24, 2024

Adagrasib receives accelerated approval for patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC).

FDA 103

FDA 103